Effective control of sickle cell disease with hydroxyurea therapy

Indian Journal of Pharmacology

Volumn 42, Issue 1, 2010, Pages 32-35

  Singh, Harminder ^a   Dulhani, Navin ^a   Kumar, Bithika N ^a   Singh, Prabhakar ^a   Tiwari, Pawan ^a  

^a Government Medical College   (India)

Author keywords

Fetal hemoglobin; Hydroxyurea; Sickle cell anemia; Sickle cell disease

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

ACUTE CHEST SYNDROME; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG DOSE ESCALATION; ELECTROPHORESIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; NEUTROPENIA; PROSPECTIVE STUDY; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; STROKE; STUDENT T TEST;

EID: 77951691263     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.62409     Document Type: Article

References (24)

1. Williams VL. Pathways of innovation: A history of the first effective treatment for sickle cell anemia. Perspect Biol Med 2004;47:552-63
2. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: The European experience. Am J Pediatr Hematol Oncol 1994;16:18-21
3. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: nvestigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332:1317-22.
4. Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2000. p. 2-17
5. Bunn HF. Induction of fetal hemoglobin in sickle cell disease. Blood 1999;93:1787-9
6. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study: A phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-4.
7. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022-6.
8. Noguchi CT, Rodgers GP, Serjeant GR, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988;318:96-9
9. Platt OS, Thorington DB, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991;325:11-6
10. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1.
11. Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-65.
12. The Management of Sickle Cell Disease. National Heart Lung and Blood Institute Revised 6/2002. Available from: http://www.nhlbi.nih.gov/health/prof/ blood/sickle/sc-mngt.pdf. [accessed on 2008 Apr 13]
13. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-65.
14. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111:231-9.
15. Gladwin MT, Shelhamer JH, Ognibene FP, Pease-Fye ME, Nichols JS, Link B, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002;116:436-44.
16. A biannual newsletter of regional medical research centre for tribals, Jabalpur, April 2005. Available from: http://icmr.nic.in/000519/Newsletter- vol2No1.pdf. [accessed in 2009].
17. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88:1960-4.
18. Ferster A, Tahriri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-32.
19. Vermylen C, Fernandez-Robles E, Ninane J, Cornu G. Bone marrow transplantation in 5 children with sickle cell anemia. Lancet 1988;1:1427-8.
20. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: The European experience. Am J Pediatr Hematol Oncol 1994;16:18.
21. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med 1995;332:1317-22.
22. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-65.
23. Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A. Hydroxyurea therapy in 49 patients with major beta thalassemia. Arch Iran Med 2009;12:295-7.
24. Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestation of hydroxyurea therapy in childhood: Case report and review. Pediatr Dermatol 2004;21:124-7.